GLPwatch
Byetta vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCByetta (exenatide by AstraZeneca) and Xultophy (liraglutide by Novo Nordisk) are both injectable medications for type 2 diabetes. Byetta uses the active ingredient exenatide, while Xultophy uses liraglutide. Both are taken as subcutaneous injections, meaning they’re given under the skin with a needle.
AI summary of the sources below.
| Byetta | Xultophy | |
|---|---|---|
| Active ingredient | exenatide | liraglutide |
| Manufacturer | astrazeneca | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes | type 2 diabetes |
| Label updated | 2025-09-02 | 2025-10-14 |